{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:28:03Z","timestamp":1793647683190,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ebiom.2024.104966","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T23:13:44Z","timestamp":1705360424000},"page":"104966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase \u2161 study"],"prefix":"10.1016","volume":"100","author":[{"given":"Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayinuer","family":"Aili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianli","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ebiom.2024.104966_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.ebiom.2024.104966_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155311","article-title":"Biomarkers in colorectal cancer: current Research and future prospects","volume":"21","author":"Ogunwobi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2024.104966_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/13543781003593962","article-title":"Colorectal cancer in review: the role of the EGFR pathway","volume":"19","author":"Saif","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"33","key":"10.1016\/j.ebiom.2024.104966_bib4","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/JCO.19.01977","article-title":"Negative predictive biomarkers in colorectal cancer: PRESSING ahead","volume":"37","author":"Sundar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ebiom.2024.104966_bib5","author":"Food and Drug Administration"},{"issue":"5","key":"10.1016\/j.ebiom.2024.104966_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncol"},{"issue":"22","key":"10.1016\/j.ebiom.2024.104966_bib7","doi-asserted-by":"crossref","first-page":"33391","DOI":"10.18632\/oncotarget.8516","article-title":"Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ebiom.2024.104966_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.104966_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1186\/s12885-022-10147-9","article-title":"Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS\/NRAS\/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ebiom.2024.104966_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081941","article-title":"Biomarker-guided anti-Egfr rechallenge therapy in metastatic colorectal cancer","volume":"13","author":"Ciardiello","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ebiom.2024.104966_bib11","first-page":"e117","article-title":"Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice","volume":"18","author":"Bekaii-Saab","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ebiom.2024.104966_bib12","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.2147\/CMAR.S215533","article-title":"Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"8","key":"10.1016\/j.ebiom.2024.104966_bib13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jtho.2016.11.2235","article-title":"Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer","volume":"12","author":"Mao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2024.104966_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2016.08.010","article-title":"Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer","volume":"68","author":"Price","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2024.104966_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.104966_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6603018","article-title":"Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial","volume":"94","author":"Vincenzi","year":"2006","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.ebiom.2024.104966_bib19","doi-asserted-by":"crossref","first-page":"22257","DOI":"10.18632\/oncotarget.8076","article-title":"Mutations of KRAS\/NRAS\/BRAF predict cetuximab resistance in metastatic colorectal cancer patients","volume":"7","author":"Hsu","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ebiom.2024.104966_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2016.309","article-title":"A\u00a0phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ebiom.2024.104966_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2024.104966_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ebiom.2024.104966_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djab112","article-title":"Prognostic and predictive impact of primary tumor sidedness for previously untreated advanced colorectal cancer","author":"Yin","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ebiom.2024.104966_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-016-2358-2","article-title":"Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000486338","article-title":"Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis","volume":"94","author":"Petrelli","year":"2018","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib26","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1245\/s10434-009-0811-z","article-title":"KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy","volume":"17","author":"Siddiqui","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"7407","key":"10.1016\/j.ebiom.2024.104966_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2024.104966_bib28","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/annonc\/mdx401","article-title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","volume":"28","author":"Sanz-Garcia","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.104966_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40880-019-0374-8","article-title":"CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial","volume":"39","author":"Shi","year":"2019","journal-title":"Cancer Commun"},{"issue":"2","key":"10.1016\/j.ebiom.2024.104966_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020147","article-title":"A\u00a0simplified genomic profiling approach predicts outcome in metastatic colorectal cancer","volume":"11","author":"Capalbo","year":"2019","journal-title":"Cancers"},{"issue":"30","key":"10.1016\/j.ebiom.2024.104966_bib31","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.3748\/wjg.v22.i30.6944","article-title":"Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy","volume":"22","author":"Lo Nigro","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ebiom.2024.104966_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092340","article-title":"Emerging roles of C-myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer","volume":"20","author":"Elbadawy","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.ebiom.2024.104966_bib33","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-10-0163","article-title":"Receptor tyrosine kinase coactivation networks in cancer","volume":"70","author":"Xu","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ebiom.2024.104966_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030638","article-title":"c-MYC expression is a possible keystone in the colorectal cancer resistance to EGFR inhibitors","volume":"12","author":"Strippoli","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ebiom.2024.104966_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4248971","article-title":"RAS\/BRAF circulating tumor DNA mutations as a predictor of response to first-line chemotherapy in metastatic colorectal cancer patients","volume":"2018","author":"Yao","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/cas.13972","article-title":"Clinical utility of circulating tumor DNA for colorectal cancer","volume":"110","author":"Osumi","year":"2019","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.ebiom.2024.104966_bib37","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-20-4699","article-title":"The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer","volume":"27","author":"Manca","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ebiom.2024.104966_bib38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/1381612826666201007163116","article-title":"The clinical impact of quantitative cell-free DNA, KRAS, and BRAF mutations on response to anti-EGFR treatment in patients with metastatic colorectal cancer","volume":"27","author":"Moradi-Marjaneh","year":"2021","journal-title":"Curr Pharm Des"},{"issue":"22","key":"10.1016\/j.ebiom.2024.104966_bib39","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1158\/1078-0432.CCR-17-3377","article-title":"Impact of emergent circulating tumor DNA RAS mutation in panitumumab-treated chemoresistant metastatic colorectal cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ebiom.2024.104966_bib40","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s10147-020-01691-0","article-title":"Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy","volume":"25","author":"Yamada","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2024.104966_bib41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1158\/1078-0432.CCR-18-2072","article-title":"Evaluation of emergent mutations in circulating cell-free DNA and clinical outcomes in patients with metastatic colorectal cancer treated with panitumumab in the ASPECCT study","volume":"25","author":"Peeters","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2024.104966_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdx504","article-title":"Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann Oncol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642400001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642400001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:27:37Z","timestamp":1762457257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642400001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"alternative-id":["S235239642400001X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.104966","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase \u2161 study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.104966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104966"}}